Latest news for Carlin Gold (OTC:CGDCF) Stock

Carlin Gold Corp is an exploration company. The firm is focused on Carlin-type gold exploration in Nevada. Its projects are the Cortez Summit Property, and Yukon Joint Venture Property among others. The company operates in Canada and the United States. It has one operating segment mineral exploration and development.

CARLIN GOLD CORP NEW by Carlin Gold Corp.

Carlin Gold Corp

SIRI

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

The Warren Buffett-led Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) recently became one of a limited number of companies to pass the <a href="https://www.benzinga.com/top-stories/24/08/40604676/warren-buffetts-berkshire-hathaway-breaks-1-trillion-poll-points-to-big-pharma-not-tech-as-next-cont">$1 trillion market capitalization.</a>
The rising valuation of the conglomerate over the years has helped add to the wealth of the many investors who have trusted the vision of Buffett, including his sister Bertie Buffett Elliott.
Investing in Berkshire Hathaway: Elliott, who at 90 years old is the younger sister of<a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig"> the legendary investor, </a>shared her story of investing in Berkshire Hathaway in a May 2024 interview.
Buffett credited his sister in a Berkshire Hathaway annual letter as being a smart investor and someone who reads newspapers every day. His sister realized that it was her older brother who was the smart investor and went all-in on believing in his investment strategy.
"I figured out that Warren was better at it than I was. That was easy," Elliott <a href="https://www.youtube.com/watch?v=wr07I1nLp-Y">recalled </a>in an interview with CNBC's Becky Quick.
While the move seemed simple in hindsight, Elliott revealed it took some adjusting, particularly when it came to Berkshire Hathaway's no-dividend policy.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
"I was in a place in my life where I wanted some dividends," she explained. "Once I got over that hump and realized&#8230; I can decide when I declare a dividend&#8230; by selling some stock. And it's capital gains instead of regular income tax. And that's good."
This strategy allowed Elliott to customize her financial withdrawals while benefiting from the growing value of Berkshire Hathaway stock. Over time, she became confident in her decision to stay fully committed to her brother's company, despite occasional temptations from brokers and investment opportunities.
"Luckily, I didn't even have to think about it much," Elliott said. "I knew I was all in with Warren and still am all the way."
For Elliott, her relationship with her brother goes beyond business. Despite his global success, she still views him as "my big brother." While the world may see him as a financial titan, Elliott feels fortunate to have grown up with a sibling who has always looked out for her. "He's always been a wonderful big brother. And I love him. And I feel so lucky that he's my big brother."
This article was partially written using artificial intelligence and was reviewed by Benzinga editors.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Education

Success Stories

Warren Buffett's Sister Went 'All In' On Berkshire Hathaway – And Never Looked Back

Election forecaster and historian Allan Lichtman has made his final prediction on whether Donald Trump or Kamala Harris will win the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a>
 What Happened: Several months ago, Lichtman <a href="https://www.benzinga.com/general/politics/24/07/40070258/trump-vs-harris-election-forecaster-with-9-out-of-10-accurate-predictions-gives-this-candidate-t">shared his preliminary findings </a>based on a 13-key system he created, but said the forecast would be updated after the Democratic National Convention.
Ahead of the<a href="https://www.benzinga.com/general/politics/24/09/40782598/harris-vs-trump-how-to-watch-2024-presidential-debate-rule-disputes-and-key-topics-for-voters"> first presidential debate</a> between Trump and Harris, set for Sept. 10, Lichtman has made his prediction for the 2024 election and shared his winner of each of the 13 keys, as <a href="https://www.nytimes.com/2024/09/05/opinion/allan-lichtman-trump-harris-prediction.html">shared </a>with the New York Times.
Here's a look at the "13 Keys to the White House" from Lichtman, which provide true and false answers and keys that favor one candidate over the other.
<ol>
<li>Midterm Gains: Democrats did better than expected in the 2022 election, but lost seats, making key false, good for Trump</li>
<li>Incumbent: Biden withdrew from race, costing Democrats the key, good for Trump</li>
<li>Primary Contest: Democrats united behind Harris after Biden withdrew, key is true, good for Harris</li>
<li>Third-Party Candidate: With Robert F. Kennedy Jr. suspending his campaign, the key is now true, good for Harris</li>
<li>Economy Is Strong: Lichtman said "the economy is not in a recession" and the key is true, good for Harris</li>
<li>Economic Growth: Lichtman said economic growth is far ahead of previous terms making the key true, good for Harris</li>
<li>Policy Changes: The historian names items like the Chips Act, rejoining the Paris Agreement and the Inflation Reduction Act as making the key true, good for Harris</li>
<li>Social Unrest: Lichtman said nothing massive has happened to make the key false, but it could flip with schools in session and controversy on Middle East policy, good for Harris</li>
<li>White House Scandal: Key is true as there is no bipartisan recognition of corruption that implicates the president himself, Lichtman said, can't be a family member like Hunter Biden, good for Harris</li>
<li>Incumbent Charismatic: Harris does not meet the requirements of a once-in-generation candidate, key is false, good for Trump</li>
<li>Challenger Charismatic: Lichtman said that while some people think Trump is God, he doesn't meet the once-in-a-generation candidate requirement, key is true, good for Harris</li>
<li>Foreign Policy Failure: Currently false, but could flip, not being counted</li>
<li>Foreign Policy Success: Currently false, but could flip, not being counted</li>
</ol>
The 13-key point system sees Harris win eight, Trump win three and two still undecided.
"Kamala Harris will be the next president of the United States," Lichtman said.
Lichtman said he is standing behind the prediction and even the two foreign policy or social unrest keys flipping will not be enough for Trump to win the election based on the keys method.
In the last prediction, Lichtman had Harris holding six of the 13 keys making it likely that she would win the election.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Lichtman established the 13 keys system in 1981 and has used it to make a prediction on each presidential election since 1984.
Lichtman has&nbsp;<a href="https://www.usatoday.com/story/news/politics/elections/2024/05/08/allan-lichtman-2024-prediction-election-biden-trump/73611104007/" target="_blank" rel="noreferrer noopener">correctly&nbsp;</a>predicted the outcome of nine of the past 10 presidential elections. This includes correctly predicting Trump&#8217;s win in 2016 and Biden&#8217;s win in 2020.
Lichtman&#8217;s only miss was in 2000 when he predicted&nbsp;Al Gore&nbsp;would defeat&nbsp;George W. Bush. Gore won the popular vote in the election, but lost the electoral college.
The election predictor stated in 2016 that his book and paper referred to the popular vote, which would make his 2000 prediction correct, but the 2016 prediction of Donald Trump was wrong as&nbsp;Hillary Clinton&nbsp;won the popular vote. Whether the prediction is for the popular vote winner or electoral college winner, the success rate of 90% has stayed the same over the past 10 elections.
Lichtman was among the few to accurately predict Trump's victory in 2016 (earning him a Sharpie-scribbled note from the candidate lauding the "GOOD CALL!").
"The race was tight, but the keys were right," Lichtman said in his latest prediction video recalling the 2016 race.
Immediately after the first 2024 presidential debate, between Trump and Biden, Lichtman was also quick to&nbsp;<a href="https://www.nytimes.com/2024/07/03/opinion/biden-harris-trump-democrats.html?searchResultPosition=3">warn</a>&nbsp;that Biden dropping out of the race could be a "tragic mistake for Democrats," leading him directly into an&nbsp;<a href="https://x.com/AllanLichtman/status/1814755577396142256" target="_blank" rel="noreferrer noopener">online battle</a>&nbsp;with the forecaster Nate Silver. The confidence is rooted in Lichtman's simple, history-driven model, which tunes out polls and pollsters and instead focuses on 13 true-or-false questions that he says hold the "keys" to the White House.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Andrew Angelov via Shutterstock

Politics

Trump Vs. Harris: Election Forecaster With 9 Out Of 10 Accurate Predictions Makes Final Call, Says This Person Will Be 'Next President Of The United States'

The latest equity research report from Pablo Zuanic of Zuanic &amp; Associates highlights key trends in Canada's cannabis market, noting a deceleration in recreational sales growth.
Data from StatCan reveals that sales for 2Q24 were down 4% year-over-year (YoY), contributing to a 1.3% decline year-to-date (YTD) compared to 14% growth in 1H23. In contrast, Hifyre data shows a 6% YTD growth through August.
If annualized, this growth would project a total<a href="https://www.benzinga.com/topic/canada-cannabis"> recreational market</a> size of C$5.47 billion for calendar year 2024, translating to US$102 per capita.
Get Benzinga&#8217;s exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Market Share Shifts Among Top Players</h3>
<a href="https://www.benzinga.com/topic/pablo-zuanic">Zuanic&#8217;s report </a>highlights notable shifts in market share among the top licensed producers (LPs). Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), once a dominant player, saw its share drop by 1.5 percentage points to 9.6% in August, continuing its decline over recent quarters. Decibel (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) also experienced a decline, dropping 0.9 percentage points to 5.2%.
Meanwhile, Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) experienced strong growth, increasing its market share to 7.9%, up from 6.1% a year ago, representing a 34% year-over-year growth. Similarly, Cronos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) and Organigram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) posted gains, with Cronos maintaining a steady 5.3% share (up 24% YoY), and Organigram growing its market share to 7.2%, up from 6.6% a year ago, reflecting 15% (YoY) growth.
Additionally, Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) and Cannara Biotech (unlisted) gained 0.5 points each, reaching 5.2% and 3.4% market shares, respectively.
Here is a breakdown of the major players:
<ul>
<li>Village Farms: sales grew +34% YoY, holding a 7.9% market share in August (up from 6.1% a year ago).</li>
<li>Cronos: +24% YoY growth in sales, maintaining a 5.3% share, consistent with previous quarters.</li>
<li>Organigram: +15% YoY growth in sales, with a market share of 7.2% in August, up from 6.6% a year ago.</li>
<li>Tilray: -20% YoY decline in sales, with a 9.6% market share in August, down from 10.1% earlier in the quarter.</li>
<li>Decibel: -25% YoY decline in sales, holding a 5.3% market share, down from 7.4% a year ago.</li>
</ul>
<h3 class="wp-block-heading">Format Preferences Continue To Evolve</h3>
The Canadian cannabis market is shifting towards newer product formats, with some segments outperforming others. Flower remains the largest category, accounting for 36% of sales in June-August 2024, down from 41% in 1Q23 and 57% in 1Q21. This decline reflects changing consumer preferences, as <a href="https://www.benzinga.com/markets/cannabis/24/06/39508155/900-pre-rolls-per-hour-upgrade-from-manual-to-automatic-speeds-up-joint-production-enhances-marg">pre-rolls</a> and vapes gain market share.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34625368/nasa-precision-meets-cannabis-roi-pre-rolled-infusion-robots-revolutionizing-indust">Pre-rolls</a> now represent 34% of total sales, up from 27% in 1Q23 and 17% in 1Q21. The segment grew 11% year-over-year (YoY) in the June-August period, driven by consumer demand for convenience. Decibel leads with a 10.4% share, though it fell to 9.7% in August. Tilray holds 8.3%, and Organigram has 6.4%.
<a href="https://www.benzinga.com/general/biotech/24/08/40341814/tony-starks-choice-vape-synergy-innovations-strategic-move-to-restore-brands-identity-lead-market">Vapes </a>account for 16% of sales, up from 15% in 1Q22 and 14% in 1Q21, supported by 8% yoy growth. Motif Labs leads with 20.6%, followed by Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) at 12.4%, up from 10.7% in 2Q24.
Other formats, like concentrates, edibles, beverages, and oils, hold smaller shares. Concentrates and edibles each represent 5%, while <a href="https://www.benzinga.com/topic/cannabis-beverages">beverages </a>and oils account for 2% each. Concentrates grew 5% YoY, while edibles declined by 5%. Beverages saw a 6% YoY increase, indicating gradual consumer adoption.
Read Next: S<a href="https://www.benzinga.com/markets/cannabis/24/08/40631613/sndl-wins-bid-for-indiva-secures-major-deal-to-boost-cannabis-edibles-market-share-in-canada">NDL Wins Bid For Indiva, Secures Major Deal To Boost Cannabis Edibles Market Share In Canada</a>

Analyst Color

Cannabis

Market Summary

News

Retail Sales

Markets

Analyst Ratings

Trading Ideas

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CRON

TLRY

TSXV:DB

Cannabis Flower? No, Thanks: Canadians Shift To Pre-Rolls & Vapes As Market Eyes C$5.47B

Cantourage Group SE reported its financial results for the period from January 1 to August 30, 2024, revealing revenue of EUR 24.9 million ($27.5 million). This marks a 62% increase compared to the same period in 2023, when the company had EUR 15.4 million in revenue. Moreover, revenue for the first seven months of 2024 is higher than Cantourage's total revenue for the full year 2023, which amounted to EUR 23.6 million.
&#8220;Our current business performance clearly shows that we took the right steps in preparation for the partial legalization of cannabis in Germany," <a href="https://www.cantourage.com/en/blog-posts/cantourage-group-se-verzeichnet-im-zeitraum-januar-bis-august-2024-hohere-umsatzerlose-als-im-gesamtjahr-2023">stated</a> Cantourage&#8217;s CEO Philip Schetter, according to translation. "In addition to expanding our range of high-quality cannabis products from around the world, we were able to scale our production capacities and strengthen our partnerships with growers and pharmacies just in time. This now enables us to sustainably meet the expected increase in demand. We are confident that the medical cannabis market offers significant opportunities, both now and in the future.&#8221;
According to the report, the major drivers for the revenue growth include the continued expansion of its cannabis flower business in Germany and the UK, and also the advancement of its Telecan platform, which provides an online pathway for German medical marijuana patients to access cannabis treatments. The <a href="https://www.benzinga.com/markets/cannabis/24/04/38023610/heres-what-you-need-to-know-about-weed-legalization-in-germany-that-just-took-effect">partial legalization of cannabis in Germany</a> in April 2024 also contributed to this upward trend.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40520655/25-german-cities-join-cannabis-pilot-trials-in-2024-under-new-legalization-law">25 German Cities Join Cannabis Pilot Trials In 2024 Under New Legalization Law</a>
In August 2024 alone, Cantourage achieved a record monthly revenue of EUR 4.9 million, a 188% increase compared to August 2023 (EUR 1.7 million). This surpasses the company's previous monthly record of EUR 4.1 million set in June 2024.
The Berlin-based cannabis company is projecting total annual revenue of EUR 37 million to EUR 43 million for 2024, with expectations of continued growth and a positive EBITDA for the year. The company was listed on the Frankfurt Stock Exchange in November 2022 <a href="https://www.benzinga.com/markets/cannabis/22/11/29686601/germanys-first-cannabis-start-up-lists-on-frankfurt-stock-exchange-ahead-of-legalization">under the symbol &#8220;HIGH.&#8221;</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
"The news agency Reuters reported a few months ago that there are currently around 4.5 million cannabis consumers in Germany alone. However, the market potential is enormous not only with regard to Germany—we are also currently seeing a continuous opening of cannabis markets in other European countries,&#8221; Schetter continued. &#8220;For Cantourage, this will—of that we are certain—offer extraordinary growth opportunities in the future. Our flexible business model is predestined to leverage the large market potential in Europe and generate further strong growth for our company. We continue to expect that we will achieve a positive EBITDA for the full year 2024.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40656581/cbd-of-denver-q2-revenue-jumps-37-4-yoy-amid-german-market-expansion-plans">CBD Of Denver Q2 Revenue Jumps 37.4% YoY Amid German Market Expansion Plans</a></li>
</ul>
Photo: Courtesy of&nbsp;HTWE&nbsp;via Shutterstock&nbsp;

Earnings

Eurozone

European Cannabis Producer Cantourage Reports 62% Revenue Increase, Projects Positive EBITDA

Big Lots, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) filing for <a href="https://www.benzinga.com/markets/equities/24/09/40767067/another-retailer-takes-chapter-11-route-big-lots-files-for-bankruptcy-and-agrees-to-sell-assets-">Chapter 11 bankruptcy protection</a> could signify a growth opportunity for competitor Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>), an analyst said.
The Columbus, Ohio-based discount retailer confirmed Monday that it would sell all of its assets and ongoing business operations to an affiliate of investment firm Nexus Capital Management as part of a decision that will also include closing some retail outlets.
Ollie&#8217;s may have the chance to take over closed Big Lots locations as it strives to increase store count from a current 525 outlets to a long-term saturation target of 1,300 stores, J.P.Morgan Chase analyst Matthew Boss said.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/09/40744407/top-wall-street-forecasters-revamp-big-lots-price-expectations-ahead-of-q2-earnings">Top Wall Street Forecasters Revamp Big Lots Price Expectations Ahead Of Q2 Earnings</a>
Ollie&#8217;s may also benefit from the fact that 430 of its stores are within close proximity to Big Lots stores, he said.
&#8220;We see lateral close-out retailer OLLI as a primary beneficiary of traffic gains and accelerated wallet share capture with 80-85% of OLLI's 525 store fleet within five miles of a Big Lots store,&#8221; he wrote in a note Monday.
Big Lots&#8217; plans to close 296 out of 1,392 retail locations as of Aug. 29 could help Ollie&#8217;s to grow its number of stores by 13.5% during fiscal years 2025 and 2026 after it increases the number of outlets to 560 by the end of the current fiscal year, Boss said. This growth in stores and market share could help Ollie&#8217;s grow its gross profit margin from 40.5% to 41%.
Price Action: Big Lots stayed at 50 cents per share during Monday&#8217;s trading but dropped 40.22% in after-hours trading to 30 cents. Ollie&#8217;s gained 5.92% to close at $92.48 on Monday.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/06/39183754/ollies-surges-on-strong-q1-earnings-raises-financial-outlook-amid-consumer-bargain-hunting">Ollie&#8217;s Surges On Strong Q1 Earnings: Raises Financial Outlook Amid Consumer Bargain Hunting</a></li>
</ul>
Photo: Robert V. Schwemmer via Shutterstock

Legal

OLLI

Big Lots Chapter 11 Could Mean Growth Opportunity For Ollie's Bargain Outlet, Analyst Says

Recent developments around cannabis reform as t<a href="https://www.benzinga.com/topic/2024-presidential-election">he 2024 election</a> approaches have quite a few heads spinning. Though now, as of Monday, cannabis reform advocates are likely scratching their heads. It seems that in Vice President Kamala Harris's newly launched campaign issues page, there is no mention of marijuana policy, <a href="https://www.marijuanamoment.net/harris-campaign-omits-marijuana-from-new-issues-page-as-trump-earns-praise-for-backing-legalization/">reported</a> by Marijuana Moment.
<h1 class="wp-block-heading">Wait...What?</h1>
The Harris campaign site outlines the vice president&#8217;s platform on various issues like taxes, health care, affordable housing and women&#8217;s issues, among others. It even touches on drug policy, noting Harris&#8217;s commitment to fighting the opioid epidemic and fentanyl-related deaths by making naloxone — an overdose-reversal drug — available over the counter.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40776937/trump-joins-millions-of-americans-who-support-rescheduling-cannabis-weed-industry-responds-to-fo">Trump &#8216;Joins Millions Of Americans&#8217; Who Support Rescheduling Cannabis: Weed Industry Responds To Former Pres&#8217; News</a>
<ul>
<li>Get Benzinga's exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h1 class="wp-block-heading">But Where's Cannabis Reform Policy?</h1>
Despite previous advocacy for marijuana reform, and lots of it, cannabis policy is conspicuously absent, reports the outlet, which is odd in that marijuana reform is clearly an issue that has become increasingly popular in national debates. Not to mention the recent pop cannabis enjoyed when Harris's arch-rival Donald Trump <a href="https://www.benzinga.com/markets/cannabis/24/09/40774795/trump-says-hell-reschedule-cannabis-if-elected-backs-marijuana-banking-reform-and-floridas-amend">came out</a> in support of federal marijuana rescheduling on Sunday night and declared himself all in with <a href="https://www.benzinga.com/markets/cannabis/24/08/40418144/florida-cannabis-legalization-one-poll-shows-weed-going-legal-in-november-ballot-another-thumbs-">Florida's legalization amendment</a>, to be decided in a November ballot.
This Trump shift on weed reform is important regardless of whether it's a "brazen flip-flop" as the <a href="https://www.benzinga.com/markets/cannabis/24/09/40677600/harris-campaign-slams-donald-trump-over-cannabis-shift-calls-it-brazen-flip-flop">Harris campaign labeled</a> his initial Labor Day weekend <a href="https://www.benzinga.com/markets/cannabis/24/08/40666944/donald-trump-supports-cannabis-legalization-in-florida-game-changer-and-huge-blow-to-ron-desanti">announcement</a> about the topic.
At this point, it almost doesn't matter that the <a href="https://www.benzinga.com/markets/cannabis/24/05/38880719/biden-announces-monumental-marijuana-rescheduling-doj-to-take-next-steps" target="_blank" rel="noreferrer noopener">Biden-Harris administration</a> successfully distinguished itself from Trump's approach to drug policy, which until recently was relatively unknown except for his <a href="https://www.benzinga.com/markets/cannabis/22/11/29741741/trump-announcement-death-to-drug-dealers-and-beautiful-american-flag-on-mars">comments about executing drug dealers</a>. One has to wonder whether the Biden team talked a bigger game than it was intending to play. And, judging by Harris&#8217;s failure to mention her cannabis policy position in her campaign page, maybe there's no game at all.
As polling indicates growing support for cannabis legalization, among Democrats as well as Republicans, Harris's decision to leave out the issue could cost her key voter support. Trump's newfound cannabis stance may resonate with advocates of marijuana reform who are willing or able to overlook his other policies.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40776688/texans-want-weed-decriminalized-majority-supports-easing-cannabis-penalties-recent-poll-shows">Texans Want Weed Decriminalized: Majority Supports Easing Cannabis Penalties, Recent Poll Shows</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Trump Applauded For Backing Marijuana Legalization While Harris Omits Cannabis Reform From Campaign Issues Page

Sirius XM Holdings will have a single outstanding series of common stock and will begin trading at market open on Tuesday, September 10, 2024 on the Nasdaq Global Select Market under the symbol &quot;SIRI&quot;.
Liberty Media&#39;s Liberty Formula One common stock and Liberty Live common stock will continue trading following the Split-Off and Merger on the Nasdaq Global Select Market or the OTC Markets, as applicable.

FWONA

Liberty Media And Sirius XM Report Completion Of Split-Off And Merger; New Sirius Is Now An Independent Public Company Separate From Liberty Media

SS&amp;C&#39;s Managed Fund Administration team will provide unit registry services to 88 BT-managed funds, including investor servicing and unit registry websites for digital account access and transactions.

Contracts

SSNC

Australia's BT Signs Long-Term Agreement With SS&C Global Investor And Distribution Solutions For Unit Registry Services

Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) announced a major milestone on Monday with the initiation of the first clinical trial site in Australia for its Phase IIb study on nature-derived <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> as a potential treatment for Adjustment Disorder in patients receiving palliative care. This development marks a key step toward advancing <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-based treatments</a> in the healthcare industry.
The trial, conducted in partnership with Fluence, a leader in psychedelic therapy research, and iNGENū CRO Pty Ltd, a renowned Australian clinical research organization, aims to explore the efficacy of Psyence's naturally sourced psilocybin drug, <a href="https://www.benzinga.com/markets/cannabis/23/03/31444645/psychedelic-research-expands-in-australia-with-palliative-care-partnership-new-mdma-analog-portf">PEX010</a>. As the company <a href="https://www.globenewswire.com/news-release/2024/09/09/2942714/0/en/Psyence-Biomed-Announces-Initiation-of-First-Trial-Site-in-Australia-for-its-Phase-IIb-Study-of-Nature-Derived-Psilocybin-as-a-Potential-Treatment-for-Adjustment-Disorder-in-Pallia.html">stated</a>, patient screening is set to begin immediately, with the first subject expected to be randomized in October.
<h3 class="wp-block-heading">A Critical Advancement For Psychedelic Therapeutics</h3>
Dr. Clive Ward-Able, medical director of Psyence Biomedical, expressed enthusiasm about the trial's progression. &#8220;The imminent activation of the first trial site and patient screening for this trial represents a significant milestone for our company and a positive step forward for the advancement of psychedelic-based therapeutics generally,&#8221; he said. He emphasized that data from the study, expected in the second half of 2025, could pave the way for a pivotal Phase III clinical program.
The study will investigate the effects of psilocybin on patients suffering from Adjustment Disorder, particularly those dealing with life-limiting cancer diagnoses. The randomized, double-blind, placebo-controlled trial will evaluate two therapeutic doses of psilocybin (10mg and 25mg) against an active low-dose comparator (1mg) in conjunction with psychotherapy, enrolling 87 patients.
<h3 class="wp-block-heading">Promising Partnerships Driving Innovation</h3>
Veronika Simic, senior clinical project manager at iNGENū, highlighted the potential of psilocybin in addressing unmet mental health needs. &#8220;We believe psilocybin holds great promise as a treatment for a broad range of mental health conditions,&#8221; Simic stated. She also reaffirmed iNGENū's commitment to efficiently advancing the study in collaboration with Psyence Biomedical.
The <a href="https://www.benzinga.com/news/24/07/39966103/why-psyence-biomedical-pbm-stock-is-skyrocketing">export of PEX010 to Australia</a> earlier this year was a crucial preparatory step, and the trial site's activation signals significant progress toward exploring the therapeutic potential of naturally derived psilocybin.
Cover image made with AI

Psychedelics

Press Releases

Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care

A rising valuation of NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in 2024 has helped boost the wealth of Jensen Huang, the co-founder and CEO of the company that was once created inside<a href="https://www.benzinga.com/general/social-media/24/03/37879478/humble-beginnings-like-nvidia-reddit-was-founded-inside-a-restaurant"> a Denny's restaurant.</a>
What Happened: Nvidia stock has risen significantly over the last several years, thanks to a boom of the <a href="https://www.benzinga.com/topic/artificial-intelligence">artificial intelligence sector</a> and the company's dominant market share for several related items.
While shares of Nvidia have fallen in recent months<a href="https://www.benzinga.com/news/earnings/24/08/40613050/nvidia-q2-earnings-guidance-top-street-view-as-ai-fuels-record-data-center-revenue-gross-margin-fal"> after quarterly earnings</a>, the stock remains up over 119% year-to-date as seen on the <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090924">Benzinga Pro chart </a>below.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090924"><img loading="lazy" decoding="async" width="1001" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09163329/Screenshot-170.png" alt="" class="wp-image-538330" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09163329/Screenshot-170.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09163329/Screenshot-170-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09163329/Screenshot-170-768x387.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Nvidia is currently valued at $2.60 trillion, which comes 16 months after passing a $1 billion market capitalization.
Huang has a wealth of $90.5 billion, ranking 18th according to <a href="https://www.bloomberg.com/billionaires/">Bloomberg</a>. While Huang hasn't cracked the top 10 list yet and would currently need to hit a wealth of $130 billion, the Nvidia co-founder is one of the fastest risers among the world's richest people.
Huang's wealth is up $46.4 billion year-to-date in 2024.
That figure is more than the combined $41.83 billion gained by Elon Musk, Jeff Bezos and Bill Gates. Musk, Bezos and Gates currently rank first, second and fifth, respectively, with the current wealth and year-to-date gains.
<ul>
<li>Elon Musk: $237 billion, +$7.73 billion year-to-date</li>
<li>Jeff Bezos: $195 billion, +$17.9 billion year-to-date</li>
<li>Bill Gates: $157 billion, +$16.2 billion year-to-date</li>
</ul>
The gain by Huang is one of the largest year-to-date gains, trailing only Meta Platforms CEO Mark Zuckerberg, who is up $49.9 billion and listed fourth at $178 billion.
Seventeen of the top 18 richest people have added to their wealth in 2024 with third-place Bernard Arnault, CEO of LVMH, down $26.8 billion year-to-date.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: With Nvidia shares trading lower after second-quarter financial results, many analysts see a<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40628887/nvidia-analysts-say-pullback-is-buying-opportunity-pushing-ai-envelope-too-signific"> potential buying opportunity </a>and call the semiconductor company one of the best ways to play the growth of artificial intelligence.
Huang's wealth is mostly tied to the stock performance of Nvidia, which means he could continue to climb up the billionaires&#8217; list if the semiconductor company can outperform the market and other stocks tied to those on the list.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Entertainment

Management

NVDA

Jensen Huang Added As Much To His Wealth In 2024 As Musk, Bezos, Gates Combined

U. S. Steel Reveals Roll Out Of ZMAG Carbon Flat Rolled Coated Steel Product

Recent research from Northwell Health, published in late August in the journal Cannabis and Cannabinoid Research, indicates that marijuana users may face better outcomes when battling COVID-19, including lower rates of severe infections and reduced likelihood of intubation or death. This promising development points to the potential immunomodulatory effects of <a href="http://benzinga.com/cannabis">cannabis</a>, which could lessen dangerous inflammation during infection.
<h3 class="wp-block-heading">Cannabis Users Show Lower COVID-19 Mortality</h3>
The <a href="https://www.liebertpub.com/doi/10.1089/can.2024.0048">study</a> analyzed data from the National Inpatient Sample Database, comparing hospital admissions for COVID-19 among cannabis users and non-users. Adjusting for various factors like age, gender, and comorbidities, the findings, as <a href="https://www.forbes.com/sites/ajherrington/2024/09/05/marijuana-users-had-better-covid-19-outcomes-new-study-shows/">reported</a> by Forbes, revealed a significant reduction in mortality and severe complications such as lung failure among cannabis users. Specifically, the mortality rate among non-users was 5.1%, nearly double the 2.8% observed in cannabis users. Additionally, cannabis users tended to have shorter hospital stays, averaging 6.4 days compared to 7.0 days for non-users.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Cautions Noted Despite Positive Findings</h3>
However, despite these encouraging results, experts urge caution. Dr. Benjamin Caplan, a cannabis <a href="https://www.benzinga.com/topic/dr-benjamin-caplan">expert</a> and author consulted by Forbes, highlighted potential limitations in the study, such as challenges in adequately matching study subjects and absence of crucial data, including patient inflammation levels and the specific cannabis products used.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40722243/cbd-increases-effect-of-thc-new-study-finds-quite-the-opposite-of-popular-belief">CBD Increases Effect Of THC, New Study Finds &#8211; Quite The Opposite Of Popular Belief</a>
<h3 class="wp-block-heading">Mixed Research Findings On Cannabis And COVID-19</h3>
The study's <a href="https://www.benzinga.com/markets/cannabis/23/10/35257022/cannabis-consumers-who-had-covid-19-experienced-better-outcomes-than-nonusers-new-study-shows">preliminary results</a> as well as previous research also support the potential association between cannabis and reduced COVID-19 severity. For instance, <a href="https://www.benzinga.com/markets/cannabis/22/01/25021545/cannabis-and-covid-cannabinoid-acids-found-in-hemp-can-prevent-and-treat-coronavirus-infection-n">a 2022 study by researchers from Oregon State University</a> showed that certain cannabinoid acids in cannabis could prevent the SARS-CoV-2 virus from entering human cells in vitro by binding to its spike protein, suggesting a possible preventive role against the virus.
Earlier research cited in the Forbes article presents a mixed view: <a href="https://www.benzinga.com/general/biotech/24/01/36582743/cannabis-and-covid-preventive-and-long-term-therapeutic-approach-revealed-in-new-study">Canadian studies suggest cannabinoids might reduce COVID-19 severity</a> by hindering viral entry and easing oxidative stress. Conversely, a University of Washington study linked marijuana use with increased severe COVID-19 risks, underscoring that no evidence supports smoking cannabis as a preventive or curative measure for the virus.
As <a href="http://benzinga.com/topic/cannabis-research">cannabis research</a> progresses, more studies are vital to fully understand its potential health benefits and risks, particularly given the long history of prohibition that has stifled scientific exploration in this emerging field.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40742396/mounting-research-supports-cannabis-as-health-care-tool-plant-compounds-relieve-endometriosis-pa">Mounting Research Supports Cannabis As Health Care Tool: Plant Compounds Relieve Endometriosis Pain And Reduce Fatigue, Studies Find</a></li>
</ul>
Photo: Benzinga edit with sources from <a href="https://unsplash.com/@fusion_medical_animation?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Fusion Medical Animation </a>and <a href="https://unsplash.com/@girlwithredhat?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Girl with red hat</a> on <a href="https://unsplash.com/s/photos/hemp?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText" target="_blank" rel="noreferrer noopener">Unsplash</a>.

Health Care

Cannabis Use Linked To Improved COVID-19 Outcomes, New Study Suggests

Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACB#TSX">ACB</a>) and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, announced on Monday the launch of the newly developed Luo CBD lozenge.
<h3 class="wp-block-heading">What Happened</h3>
The product was developed by Vectura Fertin Pharma, and represents the company's first medical cannabis CBD lozenge to be introduced in Canada.
The move follows the announced commercial collaboration between Vectura Fertin Pharma's subsidiary Cogent International and the Edmonton, Alberta-based company to leverage Aurora&#8217;s Canadian medical cannabis patient platform.
Cogent manufactures, packages and labels the CBG lozenge, a novel dissolvable format and is easy to dose.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40219701/aurora-cannabis-shares-jump-on-q1-fy25-earnings-global-medical-marijuana-yields-record-revenue-o">Aurora Cannabis Shares Jump On Q1 FY25 Earnings, Global Medical Marijuana Yields Record Revenue Of $343M</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Why It Matters</h3>
Through Aurora&#8217;s patient platform, Cogent will gain access to patient feedback on the CBD lozenge, which will be used to validate the product proposition and build real-world patient data to inform future products.
&#8220;As the leading provider of medical cannabis in Canada, the launch of the newly developed Luo CBD lozenge on our platform is a significant and exciting milestone at the beginning of our strategic collaboration with Vectura Fertin Pharma," said Aurora CEO Miguel Martin. "We are committed to bringing innovative solutions to patients and this launch reinforces our position at the forefront of Canada&#8217;s medical cannabis industry.&#8221;
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09083545/ccc-oct-24-banner__1_-13.gif" alt="" class="wp-image-537351" /></a></figure>
<h3 class="wp-block-heading">What's Next</h3>
The two companies are open to exploring opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.
<h3 class="wp-block-heading">ACB Price Action</h3>
Aurora's shares traded 2.96% higher at $5.57 per share during the pre-market session on Monday morning.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40567166/nasdaq-cannabis-titan-aurora-could-boost-31-sales-surge-with-this-new-cbd-lozenge-partnership">NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership</a></li>
</ul>

TSX:ACB

Aurora's CBD Lozenge Partnership: Here's Where To Find The New Product

A new study published in Drug and Alcohol Dependence Reports found that usage among adults has surged, but teenage cannabis use maintained its yearly levels.
The study, which analyzed data from over 543,000 people between 2013 and 2022, offers a closer look at how legalization and shifting attitudes have reshaped the social adoption of cannabis, <a href="https://www.theguardian.com/society/article/2024/sep/07/cannabis-use-survey-teenagers">reported</a> The Guardian.
Another notable finding is the rise in cannabis consumption among adults with higher incomes and college degrees. Researchers crunched the numbers coming from the<a href="https://www.samhsa.gov/data/data-we-collect/nsduh-national-survey-drug-use-and-health"> National Survey on Drug Use and Health</a> (NSDUH) to examine trends across various demographics. 
<h3 class="wp-block-heading">Teen Use Holds Steady</h3>
Despite concerns that cannabis legalization might drive increased use among teenagers, the data shows otherwise. The outcome is strong, since it <a href="https://www.benzinga.com/markets/cannabis/23/12/36228666/the-kids-are-alright-government-study-finds-teen-cannabis-use-holds-steady-despite-increased-sta">coincides with a previous study</a> on the matter. 
In fact, while use among teens has remained between 6% and 7% over the last decade according to the new study, previous studies have even showed a <a href="https://www.benzinga.com/markets/cannabis/23/05/32242259/cdc-survey-shows-legal-weed-dispensaries-have-helped-curb-teen-cannabis-use">decrease</a> among this demographic group.
&#8220;We expected to see an increase, especially with the broader legalization and availability,&#8221; said Dr. Delvon Mattingly, lead author of the study and a behavioral science professor at the University of Kentucky. &#8220;But the data show that teen use has remained surprisingly flat.&#8221;
Experts believe that strict regulations preventing dispensaries from selling to minors have played a role. Dispensaries often enforce age verification using ID scans, which reduces the chances of illegal access.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">Daily Cannabis Consumption Outpaces Daily Alcohol Use In The US For The First Time, New Study Shows</a>
<h3 class="wp-block-heading">Cannabis Use Climbs Among Rich And Educated Adults</h3>
Overall cannabis consumption has increased among adults, particularly those with higher incomes and college degrees. Individuals in households earning $75,000 or more per year nearly doubled their usage, from 5.89% in 2013 to 13.20% in 2022. Likewise, usage among college graduates rose sharply from 4.48% to 12.42% during the same period.
This increase highlights how legalization has led to the normalization of cannabis. Experts suggest that changing public attitudes have fueled this increase, especially among wealthier, educated Americans. 
&#8220;With legalization, cannabis has become more normalized, especially among higher-income groups,&#8221; Mattingly noted. &#8220;People are using it recreationally and for medical reasons, particularly for managing pain and anxiety.&#8221;
<h3 class="wp-block-heading">Shifting Public Perception</h3>
Jordan Gette, a postdoctoral fellow at the Rutgers Center of Alcohol and Substance Use Studies, noted, &#8220;We see celebrities and professional athletes endorsing cannabis products, which has helped shed its stigma.&#8221; 
This shift has also been aided by dispensaries opening in affluent areas, making cannabis more accessible to wealthier demographics.
Medical cannabis also played a role in this shift. In states where medical cannabis is legal, many older adults now turn to it<a href="https://www.benzinga.com/24/07/39774432/new-study-shows-high-use-of-medical-cannabis-for-chronic-pain-and-arthritis-in-older-patients"> to treat chronic conditions</a>. &#8220;Higher income is often correlated with access to healthcare, and medical cannabis is increasingly being used to manage chronic conditions like pain,&#8221; Mattingly added.
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">Racial And Ethnic Patterns</h3>
The study also brought to light notable racial and ethnic trends. 
Statistics show a higher prevalence among non-Hispanic multiracial individuals, with over 25% reporting having used in 2022. This group had the highest rate of cannabis consumption compared to other racial and ethnic categories.
Mattingly emphasized the importance of continuing research that includes multiracial individuals. &#8220;These findings underscore the importance of including multiracial populations in future research,&#8221; Mattingly said.
<h3 class="wp-block-heading">Cannabis And Hallucinogen At Record Highs</h3>
In addition to these findings, another recent study from the University of Michigan's Monitoring the Future (MTF) survey showed that cannabis and hallucinogen among U.S. adults reached <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">a historically high level in 2023</a>.
According to the survey, 42% of young adults aged 19 to 30 reported using cannabis in the past year, with 10% engaging in daily consumption. Similarly, among adults aged 35 to 50, 29% reported having consumed in the past year, with 8% using it daily.
The MTF survey also noted an increase in hallucinogen use.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">Cannabis And Hallucinogen Consumption Hit All Time Highs In 2023 While Tobacco And Alcohol Declined</a></li>
</ul>

Cannabis Use Rose Among US Adults Over 10 Years, But Kept Steady In Teens, Finds New Study

EZGO

EZGO Technologies H1 Revenues $8.6M, Up From $5.16M Last Year

Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) shares are trading lower after Monday's closing bell. The company announced it has commenced a public offering of $1.35 billion (27 million shares) of Series C mandatory <a href="https://www.benzinga.com/pressreleases/24/09/b40782527/hewlett-packard-enterprise-announces-proposed-public-offering-of-mandatory-convertible-preferred-s">convertible preferred stock.&nbsp;</a>
The Details: Hewlett Packard also expects to grant the underwriters a 30-day option to purchase up to an additional $150 million (3 million shares) of preferred stock to cover over-allotments, if any. 
Hewlett Packard said it intends to use the net proceeds from the offering to fund all or a portion of the consideration for the previously announced pending acquisition of Juniper Networks, Inc., to pay related fees and expenses, and, if any proceeds remain, for other general corporate purposes.
Read Next: <a href="https://www.benzinga.com/news/24/09/40774644/dell-technologies-to-included-in-s-p-500-whats-going-on-with-the-stock">Dell Technologies To Be Included In S&amp;P 500: What&#8217;s Going On With The Stock?</a>
The company said each share of preferred stock will have a liquidation preference of $50 per share,&nbsp; and each share will automatically convert into a number of shares of common stock on or around Sept. 1, 2027, based on the applicable conversion rate.
Hewlett Packard intends to apply to list the preferred stock on the New York Stock Exchange under the symbol &#8220;HPEPrC.&#8221;
HPE Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Hewlett Packard shares are down 6.08% after-hours at $16.53 at the time of publication Monday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40777175/whats-going-on-with-gamestop-stock-ahead-of-earnings">What&#8217;s Going On With GameStop Stock Ahead Of Earnings?</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Movers

Tech

What's Going On With Hewlett Packard Stock After-Hours?

Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) has outperformed the market over the past 10 years by 15.96% on an annualized basis producing an average annual return of 26.5%. Currently, Palo Alto Networks has a market capitalization of $111.85 billion. 
Buying $1000 In PANW: If an investor had bought $1000 of PANW stock 10 years ago, it would be worth $10,589.41 today based on a price of $344.05 for PANW at the time of writing.
<h3>Palo Alto Networks's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725917417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PANW

Here's How Much $1000 Invested In Palo Alto Networks 10 Years Ago Would Be Worth Today

Republic Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) has outperformed the market over the past 15 years by 2.99% on an annualized basis producing an average annual return of 14.56%. Currently, Republic Servs has a market capitalization of $64.48 billion. 
Buying $1000 In RSG: If an investor had bought $1000 of RSG stock 15 years ago, it would be worth $7,692.02 today based on a price of $205.30 for RSG at the time of writing.
<h3>Republic Servs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725917412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $7,700 Today

In a recent exclusive interview with Benzinga, Paul Eitelman, chief investment strategist for North America at Russell Investments, provided insights into the sectors of small-cap stocks that stand out <a href="https://www.benzinga.com/trading-ideas/small-cap-analysis">amidst economic uncertainty</a>.
While small-caps as a whole face some macroeconomic risks, Eitelman highlights several specific sectors that could offer substantial opportunities.
<h1 class="wp-block-heading">Where Small-Cap Managers Are Finding Opportunities</h1>
Eitelman notes that &#8220;dedicated small-cap managers are finding opportunities to tilt their portfolio strategies toward banks, technology and select highly indebted companies that are likely to benefit from lower interest rates going forward.&#8221; These sectors are positioned to thrive, especially as interest rates begin to decline.
Technology continues to dominate market discussions, and small-cap tech companies could be key beneficiaries of economic shifts, particularly those aligned with innovative growth areas like AI and data services.
The Russell 2000 index is one of the more popular indices tracking small cap U.S. equity. ETFs that track this index include the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), the Vanguard Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTWO#NYSE">VTWO</a>) and the Avantis US Small Cap Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVSC#NYSE">AVSC</a>). The Invesco S&amp;P SmallCap Information Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSCT#NYSE">PSCT</a>) is a lesser-known but technology-focused ETF tracking small cap companies. The top 3 holdings of this ETF are Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>), SPS Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) and Badger Meter Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>).
Read Also: <a href="https://www.benzinga.com/news/24/08/40423157/small-cap-ai-stocks-on-the-rise-3-hidden-gems-you-shouldnt-miss">Small-Cap AI Stocks On The Rise: 3 Hidden Gems You Shouldn&#8217;t Miss</a>
<h1 class="wp-block-heading">Stock Selection: Primary Driver Of Risk, Return</h1>
However, Eitelman cautions that given the high macroeconomic uncertainty, broad sector bets are risky. He recommends a more refined approach: "Our preference into high macro uncertainty is to target only modest sector tilts and let stock selection shine as the primary driver of risk and return."
This focus on stock selection over aggressive sector rotation makes sense in an environment where not all companies are equally positioned to navigate fluctuating interest rates or economic slowdowns. 
Banks, for example, are likely to benefit from a soft landing scenario, while indebted companies could see relief as rates fall. Tech remains a favorite sector due to its long-term growth prospects, even amid near-term uncertainty.
Overall, Eitelman's strategy emphasizes precision and caution, advising investors to prioritize stock-picking and avoid broad over-exposure in the small-cap space.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40749609/this-small-cap-top-pick-is-positioned-for-strong-gains-jpmorgan-sees-over-50-upside">This Small Cap &#8216;Top Pick&#8217; Is Positioned For Strong Gains, JPMorgan Sees Over 50% Upside</a></li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the <a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference on Oct. 9-10, 2024</a>, at the Chicago Marriott Downtown Magnificent Mile.
Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders.
<a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Secure your spot and get your tickets today!</a>
Photo: Borka Kiss via Shutterstock

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Comments

Carlin Gold

News

Latest news for Carlin Gold (OTC:CGDCF) Stock